The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings

被引:59
作者
Jenner, LJ
Seman, LJ
Millar, JS
Lamon-Fava, S
Welty, FK
Dolnikowski, GG
Marcovina, SM
Lichtenstein, AH
Barrett, PHR
deLuca, C
Schaefer, EJ [1 ]
机构
[1] Tufts Univ, Lipid Metab Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA
[2] Univ Penn, Dept Med, Philadelphia, PA 19004 USA
[3] Tufts Univ, Mass Spectrometry Lab, Jean Mayer USDA Hunam Nutr Res Ctr Aging, Boston, MA 02111 USA
[4] Univ Washington, NW Lipid Res Labs, Seattle, WA 98103 USA
[5] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6847, Australia
[6] Western Australia Inst Med Res, Perth, WA 6847, Australia
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2005年 / 54卷 / 03期
关键词
D O I
10.1016/j.metabol.2004.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The metabolism of apolipoproteins (apo) (a) and B-100 within plasma lipoprotein (a) [Lp(a)] was examined in the fed state in 23 subjects aged 41 to 79 years who received a primed-constant infusion of [5,5,5(-2) H(3)] leucine over 15 hours. Lipoprotein (a) was isolated from the whole plasma using a lectin affinity-based method. Apolipoprotein (a) and apoB-100 were separated by gel electrophoresis, and tracer enrichment of each apolipoprotein was measured using gas chromatography/mass spectrometry. Data were fit to a multicompartmental model to determine fractional catabolic rates (FCRs) and secretion rates (SRs). The FCRs of apo(a) and apoB-100 (mean SEM) within plasma Lp(a) were significantly different (0.220 +/- 0.030 pool/d and 0.416 +/- 0.040 pool/d, respectively; P < .001). Apolipoprotein (a) SR (0.50 +/- 0.08 mg/[kg per d]) was significantly lower than that of apoB-100 SR (1.53 +/- 0.22 mg/[kg per d]; P < .001) of Lp(a). Plasma concentrations of Lp(a) were correlated significantly with both apo(a) SR and apoB-100 SR (r = 0.837 and r = 0.789, respectively; P < .001) and negatively with apo(a) FCR and Lp(a) apoB-100 FCR (r = -0.547 and r = -0.717, respectively; P < .01). These data implicate different metabolic fates for apo(a) and apoB-100 within Lp(a) in the fed state. We therefore hypothesize that apo(a) does not remain covalently linked to a single apoB-100 lipoprotein but that it rather reassociates at least once with another apoB-100 particle, probably newly synthesized, during its plasma metabolism. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 49 条
[1]   The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor [J].
Argraves, KM ;
Kozarsky, KF ;
Fallon, JT ;
Harpel, PC ;
Strickland, DK .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (09) :2170-2181
[2]   Lp(a) lipoprotein, vascular disease, and mortality in the elderly [J].
Ariyo, AA ;
Thach, C ;
Tracy, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2108-2115
[3]   Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger - A prospective study [J].
Bostom, AG ;
Cupples, LA ;
Jenner, JL ;
Ordovas, JM ;
Seman, LJ ;
Wilson, PWF ;
Schaefer, EJ ;
Castelli, WP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07) :544-548
[4]   A PROSPECTIVE INVESTIGATION OF ELEVATED LIPOPROTEIN(A) DETECTED BY ELECTROPHORESIS AND CARDIOVASCULAR-DISEASE IN WOMEN - THE FRAMINGHAM HEART-STUDY [J].
BOSTOM, AG ;
GAGNON, DR ;
CUPPLES, LA ;
WILSON, PWF ;
JENNER, JL ;
ORDOVAS, JM ;
SCHAEFER, EJ ;
CASTELLI, WP .
CIRCULATION, 1994, 90 (04) :1688-1695
[5]  
Brewer Jr HB, 1990, LIPOPROTEIN A, P211
[6]   MODELS TO INTERPRET KINETIC DATA IN STABLE ISOTOPE TRACER STUDIES [J].
COBELLI, C ;
TOFFOLO, G ;
BIER, DM ;
NOSADINI, R .
AMERICAN JOURNAL OF PHYSIOLOGY, 1987, 253 (05) :E551-E564
[7]   MEASUREMENT OF VERY LOW-DENSITY AND LOW-DENSITY-LIPOPROTEIN APOLIPOPROTEIN (APO)-B-100 AND HIGH-DENSITY-LIPOPROTEIN APO-A-I PRODUCTION IN HUMAN-SUBJECTS USING DEUTERATED LEUCINE - EFFECT OF FASTING AND FEEDING [J].
COHN, JS ;
WAGNER, DA ;
COHN, SD ;
MILLAR, JS ;
SCHAEFER, EJ .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (03) :804-811
[8]   LIPOPROTEIN LP(A) LEVELS ARE REDUCED BY DANAZOL, AN ANABOLIC-STEROID [J].
CROOK, D ;
SIDHU, M ;
SEED, M ;
ODONNELL, M ;
STEVENSON, JC .
ATHEROSCLEROSIS, 1992, 92 (01) :41-47
[9]   Lipoprotein(a) and coronary heart disease - Meta-analysis of prospective studies [J].
Danesh, J ;
Collins, R ;
Peto, R .
CIRCULATION, 2000, 102 (10) :1082-1085
[10]   The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans [J].
Demant, T ;
Seeberg, K ;
Bedynek, A ;
Seidel, D .
ATHEROSCLEROSIS, 2001, 157 (02) :325-339